Momentum Watchlist: Four OTC Stocks That Popped On News (EPAZ, PPCB, BDPT, HMBL)

When it comes to trading OTC stocks, there are two catalysts that catch the attention of investors: news and big moves. Why? Because oftentimes, these can trigger multi-day momentum moves with the potential for solid profits.

Momentum is a key concept in the world of stock trading, and it refers to the tendency of stocks that have performed well to continue performing well in the short term. When a stock gains momentum, it can attract the attention of traders looking for opportunities to capitalize on short-term gains.

Let’s focus on stocks currently trading under $1 that saw notable gains yesterday on the OTC markets. Each of these stocks released news on March 28, updating shareholders and investors on activity within the given companies, and each saw gains on the same day.

Four stocks that released news and were up yesterday are: EPAZ, PPCB, BDPT, and HMBL.

Epazz, Inc. (OTC:EPAZ) finished the day up a whopping 63.64% on Tuesday, with a final share price of $0.013. EPAZ, a provider of drone technology, blockchain mobile apps, and cloud-based business software solutions, has announced that its subsidiary, ZenaDrone, Inc., has received a letter of support from the U.S. Air Force for its ZenaDrone 1000. The letter specifically mentions the use of the platform in drone cargo delivery, which would include blood transport among other applications.

As part of this support, ZenaDrone has been invited to work with the U.S. Air Force at an overseas base to test the ZenaDrone 1000 under real-world battlefield conditions. This will be the first time that the drone will be put into active use in a military environment.

To conduct the test, ZenaDrone will be assigned a team from the base. This presents a significant opportunity for ZenaDrone to demonstrate the capabilities of its platform and potentially open the door to future contracts with the U.S. Air Force.

Additionally, the test of the ZenaDrone 1000 by the U.S. Air Force presents an opportunity for the platform to move up to Technology Readiness Level 7 (TRL). TRLs are a way of assessing the maturity of technologies during the acquisition phase of a program on a scale from 1 to 9. A higher TRL indicates a greater level of technological maturity, with 9 being the most mature.

For those that have not been following the Zenadrone story, their drone, the ZenaDrone 1000, has been gaining attention from the U.S. military over the past few months, and the drone has been presented and showcased to both the U.S. Air Force and U.S. Army.

This opportunity opens the door for some significant revenue increases. ZenaDrone has been selected to submit a Phase II SBIR grant for external funding of the ZendaDrone 1000 cargo delivery solution. Phase II SBIR grants are generally up to $1.2 million for a two-year period and are a non-dilutive source of funding. This will be the second direct to Phase II project for ZenaDrone.

CEO Shaun Passley, Ph.D., said, “We are excited to see ZenaDrone 1000 the subject of so much attention in multiple military branches. The Air Force clearly sees value in this platform and is pushing the envelope of new testing to find out the extent of its capabilities. We are anxious to receive critical feedback from the Air Force as we transition to mass production operations. We are currently in the process of evaluating a number of suitable sites while balancing the potential commercial uses. We also hope shareholders see how we are trying to move the technology forward through the use of nondilutive funding sources.”

With the U.S. Air Force providing support for ZenaDrone’s 1000 platform, Epazz Inc.’s subsidiary has the potential for significant revenue increases and the opportunity to showcase its capabilities and potentially secure future contracts with the military, making it an appealing investment for those interested in drone technology and military applications.

Another stock that had great success on Tuesday is PPCB, which finished up 33%. Propanc Biopharma, Inc. (OTC: PPCB) is developing a potential breakthrough treatment for pancreatic, ovarian, and other cancers that utilizes pancreatic proenzymes to specifically target and eliminate cancer stem cells, thereby preventing tumor recurrence and metastasis. PPCB calls their developing cancer therapy PRP.

PRP is a mixture of two proenzymes from bovine pancreas, administered by intravenous injection. A synergistic ratio of 1:6 inhibits the growth of most tumor cells. Examples include kidney, ovarian, breast, brain, prostate, lung, liver, uterine, and skin cancers

On Tuesday, the company announced that PRP has shown effectiveness in suppressing the growth factor molecule known as TGF-, which is a growth factor molecule involved in cell proliferation, migration, survival, and death that influences tumor growth in advanced forms of cancer.

In experiments, PRP was shown to be even more effective than a well-known small molecule inhibitor of the TGF- pathway. Furthermore, PRP was found to reduce the expression of the TGF- pathway in chemoresistant tumor cells, which are cells that have become resistant to standard cancer treatments.

The company believes that PRP has the potential to become an effective cancer therapy without the side effects of standard treatments and will continue to conduct further experiments to explore its potential.

Dr. Julian Kenyon, MD, MB, ChB, Propancs Chief Scientific Officer, said, “We continue to generate convincing scientific evidence supporting PRP as a novel cancer therapy for the treatment of solid tumors, but without the side effects normally associated with standard treatment approaches. Our joint research team will continue to explore these opportunities with great interest as we advance to early-stage clinical development for PRP.”

Bioadaptives Inc. (OTC: BDPT) was up 30% at close on Tuesday. The successful day of trading followed the announcement of the signing of a non-exclusive license agreement with LY Research Corporation to market a patented product called Glucobotanic (Patent # us 8,114,444 B2) for glucose management.

Edward Jacobs, M.D.,CEO BioAdaptives, Inc. , comments, “We are very excited to be working with Dr. Yaguang Liu , LY Research , in bringing this breakthrough glucose balance and glycemic wellness supplement to the market. Dr. Liu is considered to be one of the worlds top botanical product experts. According to Statista, Around 10.5 percent of the global adult population suffered from diabetes in 2021 – by the year 2045 this number is expected to rise to over 12 percent.”

BioAdaptives, Inc. makes and sells natural plant and algae-based products that promote better health and wellness for humans and animals. Their products are designed to help with pain relief, immune system support, stress resistance, endurance, recovery from injury or illness, and anti-aging.

BDPT utilizes proprietary methods to increase the effectiveness of the nutrients in their supplements. Their products are also used for general health improvement and to enhance appearance in horses and dogs.

The final stock is HUMBL, Inc. (OTCQB: HMBL), which was up 9.76% at close on Tuesday. The increased attention could have to do with their recent company release. HUMBL announced the launch of its Artificial Intelligence (AI) and Automated Machine Learning initiatives across its consumer, commercial and Latin America business units.

The company has already secured its first commercial sales contract in its HUMBL Latin America subsidiary, with a $60,000 contract for initial deliverables and a total contract value of $195,000 over three years, pending achievement of milestones.

“Artificial intelligence is an accelerant to the principles of Web 3,” said Brian Foote, CEO of HUMBL. “The use of public data sets to create more autonomous, intelligent outcomes for consumers, as well as the corporations and governments that serve them, is an excellent use of automated machine learning technologies,” continued Foote. “The use of AI can help our clients model for more predictive outcomes around things like credit scoring, default rates, churn rates, healthcare patterns and more; driving more tailored experiences for consumer, while driving revenues and improved efficiencies for corporations and governments.”

HUMBL is also internally testing its consumer AI initiatives and the Hey BLUE virtual assistant, which is based on the company’s signature mascot, a Bored Ape Yacht Club NFT of the same name (BLUE). The company plans to scale up its consumer AI product lines across the HUMBL Platform, particularly around its planned HUMBL Pro subscription services, available across key touch points throughout the HUMBL ecosystem.

According to, the global digital platform is expected to grow significantly in the coming years. The market is estimated to have been worth US$12.8 billion in 2022 and is projected to reach a size of US$38 billion by 2030, growing at a CAGR of 14.6% during the forecast period of 2022-2030, meaning it could be a good time for investors to take a deeper dive into the sector.

CapitalGainsReport is a financial website for investors seeking nanocap and microcap opportunities. We cover macroeconomic news, sector plays, company news, technical analysis, market action alerts, and catalysts that drive price action. Please visit our site at